We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Clarient and ACORN Research Announce Partnership

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Clarient and ACORN Research Announce Partnership"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

These processes have the potential to improve oncology treatment and research that aim to deliver targeted treatments based on the specific genetic markers for each patient.

The collaboration will establish a system for the collection of a broad array of tumor-specific biomarker data at the time of the patient's initial cancer diagnosis. Clarient's expertise in cancer diagnostics, combined with ACORN's oncology network and advanced bioinformatics platform, will enable the patient's medical team to better determine the most effective treatment regimen for the patient's tumor-specific biomarker profile.

The Clarient-ACORN collaboration will also enable matching broad biomarker data with outcomes data from clinical trials and clinical practice to help identify new prognostic markers and biomarker-specific treatments. Molecular profiling will be the topic of numerous conversations as both the San Antonio Breast Cancer Symposium and the American Society of Hematology get underway this week.

"As part of our commitment to take cancer personally, we are pleased to be working together with ACORN Research to provide oncologists within their network with a full menu of molecular testing, which can help identify the unique characteristics or biomarkers of a particular cancer. This information provides pathologists with crucial information to assist oncologists in diagnosis, prognosis and treatment planning," said Ron Andrews, CEO of Clarient. "Also, the opportunity to discover new markers that could be relevant in the individualized treatment of cancer has the potential to improve mortality rates, enhance patient quality of life and reduce the cost burden on cancer treatment to both patients and payers."

"We are delighted to enter into this agreement with Clarient, a company which shares our commitment to improving patient outcomes in community oncology, where 85% of all cancer patients are treated," said Lee Schwartzberg, MD, President of ACORN Research. "Our collaboration is a leap forward in bringing the most advanced diagnostics and bioinformatics tools to accelerate the use of personalized medicine in this setting."